The study evaluated oral semaglutide in young patients with type 2 diabetes and found it delivered a superior reduction in HbA1c
The investigational therapy, MDX2003, is designed to go after cancer cells with a multi-pronged immune attack
The study is being conducted through its Japan-based pharmaceutical arm, Asahi Kasei Therapeutics Corp
Together, the companies aim to deliver an integrated toolkit for biomarker discovery and clinical research
By prioritising absolute compliance, leveraging the power of digital tools, and aligning with government policies, the sector is locking in its future leadership
Shift from approvals to digital intimation via NSWS portal aims to cut timelines and boost innovation in early-stage drug development
The Clinical Trial Application (CTA) approval clears the way for the company to launch trial locations in France and Romania
The innovation is particularly suited for bone and cartilage repair
ENFLONSIA is a long-acting monoclonal antibody designed to shield infants through a typical five-month RSV season with a single, fixed dose
The upcoming multi-center, multinational Phase 1 study will evaluate safety, tolerability, pharmacokinetics, and early signs of efficacy
Subscribe To Our Newsletter & Stay Updated
